We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Gene Cluster Predicts Lung Cancer Outcome

By HospiMedica staff writers
Posted on 10 Jun 2002
Researchers have found a cluster of genes that serves as a genetic fingerprint that can indicate which lung cancer patients have a high likelihood of failing standard treatment and which will have a better prognosis. More...
The findings were reported in the May 2002 issue of Cancer Research.

Generally, about 50-60% of lung cancer patients treated by surgery will have their cancer recur. The researchers, from Ontario Cancer Institute (OCI) at Princess Margaret Hospital (Toronto, Canada), examined more than 19,000 genes in a group of lung cancer patients and narrowed these down to 3,000 genes that seemed likely to be important. Using microarrays and the latest computer software, they further narrowed the search to a cluster of only 22 genes. These were found to be expressed differently in patients whose lung cancer reappeared after treatment than in those whose cancer did not recur within two years.

Thus, the discovery is not based on a single abnormality in any particular gene but, rather, the recognition that it is the pattern of many interconnected genes that seems to be controlled differently in lung cancer. The researchers hope to further refine the fingerprint and produce a lung-cancer specific microarray that could be tested in clinical trials.

"This genetic fingerprint is actually a pattern of genes in the lung tumor that correlated with dramatically different chances of cancer relapse,” said Dr. Ming Tsao, leader of the study and a pathologist at the hospital. "In the future, this may allow us to be much more precise in assessing risk and determining whether to be more aggressive in our treatment for some patients.”




Related Links:
Ontario Cancer Institute

Gold Member
Blood Gas Analyzer
i-Check200
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Patient Monitoring System
AlarmSense
Patient Preoperative Skin Preparation
BD ChloraPrep
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The new, inexpensive stick-on sweat sensor measures lipid levels, offering a noninvasive way to continuously monitor cholesterol and triglycerides. (Image Credit: California Institute of Technology)

Wearable Patch Enables Continuous Noninvasive Cholesterol and Triglyceride Monitoring

Cholesterol and triglyceride testing typically relies on phlebotomy and intermittent lipid panels, limiting real-time assessment of cardiovascular and metabolic risk. Noninvasive monitoring could reduce... Read more

Surgical Techniques

view channel
Image: Phasix Mesh is a fully resorbable monofilament scaffold designed for rapid tissue incorporation, combining synthetic mesh repair strength with biologic graft-like remodeling. (Photo courtesy of BD)

Resorbable Mesh Evaluated to Prevent Incisional Hernias After Abdominal Surgery

Incisional hernia is a common complication after abdominal surgery and can necessitate additional interventions and prolonged recovery. Preventive strategies remain limited, and there are currently no... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.